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Abstract 
Non-obese diabetic (NOD) mice, a model strain for human type 1 diabetes, express 
proinsulin (PI) in the thymus. However, insulin-reactive T cells escape negative selection and 
subsequent activation of the CD8
+
 T cell clonotype G9C8, which recognizes insulin B15-23 
via an αβ T cell receptor (TCR) incorporating TRAV8-1/TRAJ9 and TRBV19/TRBJ2-3 gene 
rearrangements, contributes to the development of diabetes. In this study, we used fixed 
TRAV8-1/TRAJ9 TCRα chain transgenic mice to assess the impact of PI isoform expression 
on the insulin-reactive CD8
+
 T cell repertoire. The key findings were: (i) PI2 deficiency 
increases the frequency of insulin B15-23-reactive TRBV19
+
CD8
+
 T cells and causes 
diabetes; (ii) insulin B15-23-reactive TRBV19
+
CD8
+
 T cells are more abundant in the 
pancreatic lymph nodes of mice lacking PI1 and/or PI2; (iii) overexpression of PI2 decreases 
TRBV19 usage in the global CD8
+
 T cell compartment; (iv) a biased repertoire of insulin-
reactive CD8
+
 T cells emerges in the periphery regardless of antigen exposure; and (v) low 
avidity insulin-reactive CD8
+
 T cells are less affected by antigen exposure in the thymus 
compared to the periphery. These findings inform our understanding of the diabetogenic 
process and potentially reveal new avenues for therapeutic exploitation in type 1 diabetes.  
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Autoreactive T cells are key players in the process of immune-mediated β cell destruction 
leading to type I diabetes. Developing CD4
+
CD8
+
 thymocytes that recognize self-derived 
peptide-major histocompatibility complex (pMHC) molecules via high affinity interactions 
with a clonotypically expressed T cell receptor (TCR) are typically removed by negative 
selection to prevent the egress of such autoreactive T cells. Similar deletional processes may 
also operate in the periphery (1). However, these tolerogenic mechanisms are not infallible, 
and self-derived antigen-specific T cell escape likely underpins a number of autoimmune 
diseases.  
Proinsulin (PI) is a major diabetogenic autoantigen in humans (2-5) and mice (6-10). It is 
generated from a larger pre-prohormone by cleavage of the signal peptide, then further 
processed in the pancreatic β cells to insulin, which is the metabolically active hormone. Self-
derived antigens, including PI, are expressed in the thymus (11; 12) under the control of the 
autoimmune regulator (AIRE) protein, a transcription factor found in medullary thymic 
epithelial cells (13). Central exposure to these antigens limits the development of autoreactive 
T cells. Although the MHC locus, encompassing both class I and II genes, is the most 
important genetic susceptibility factor for type 1 diabetes (14), the insulin 5’-VNTR region 
also plays a significant role by regulating PI expression in the thymus and pancreas (15). 
There are two types of PI in mice, known as PI1 and PI2, which are separately encoded in the 
genome. PI2 is expressed in the thymus and pancreas, whereas PI1 is thought to occur 
primarily in the pancreas (11; 16), with only low level expression in the thymus (17). For this 
reason, it has been suggested that PI2 may be more pivotal in the development of T cell 
tolerance. Investigation of individual PI1 (PI1
-/-
) knockout mice backcrossed to the non-obese 
diabetic (NOD) background has shown that loss of PI1 reduces the incidence of diabetes (18). 
In contrast, loss of PI2 in the corresponding PI2
-/-
 model accelerates the development of 
diabetes in 100% of mice (19). Conversely, thymic overexpression of PI2 on the MHC class 
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II promoter (NODPI2
tg
) leads to a decreased incidence of diabetes (20; 21). These findings 
suggest that PI2 is important for both central and peripheral tolerance. 
Insulin-reactive CD4
+
 and CD8
+
 T cells have both been shown to be important for the 
development of diabetes in humans and mice (6-8; 10; 22). The dominant CD8
+
 T cell 
epitope in NOD mice, insulin B15-23 (8; 22), overlaps with a longer peptide recognized by 
diabetogenic CD4
+
 T cells (23). In a study where both PI1 and PI2 were eliminated, and an 
altered insulin expressing alanine at position B16 instead of tyrosine was substituted for 
native insulin, the resulting PI1
-/-
PI2
-/-
Y16A
tg
 mice were protected from diabetes due to 
removal of the cognate CD4
+
 and CD8
+ 
autoreactive T cell epitopes (9). However, if both PI1 
and PI2 are deleted without insulin substitution, mice die very rapidly from metabolic 
problems related to insulin deficiency. It is also notable that insulin autoimmunity is required 
for the development of islet-specific glucose-6-phosphatase catalytic subunit-related protein 
(IGRP) reactivity (24; 25). Modifying the development of insulin autoimmunity may 
therefore prove to be a key therapeutic intervention. 
We previously generated a highly diabetogenic murine CD8
+
 T cell clone (G9C8) that 
expresses an αβ TCR encoded by TRAV8-1/TRAJ9 and TRBV19/TRBJ2-3 gene 
rearrangements (22). In vitro, this clone displayed potent cytotoxic and proliferative activity 
in response to islet cells. In vivo, G9C8 caused diabetes within 5-10 days in young pre-
diabetic NOD and NOD.scid mice (22). Moreover, T cells that recognize the H-2K
d
-restricted 
insulin B15-23 epitope targeted by G9C8 infiltrate the islets of NOD mice at 4 weeks of age, 
a time when very few T cells with other specificities are present (8; 26). These observations 
further suggest that CD8
+
 T cells are important in the pathogenesis of autoimmune diabetes in 
the NOD mouse model. The insulin B15-23 peptide (LYLVCGERG) binds very poorly to 
H2-K
d 
(27; 28). Consequently, relatively high peptide concentrations are required for 
exogenous recognition of this antigenic complex, which typically elicits low avidity T cells. 
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Of note, the native B15-23 sequence is conserved in humans, and common to both murine PI1 
and PI2.  
It is established that CD8
+
 T cells in humans can recognize antigenic peptides derived 
from pre-proinsulin and destroy β cells (4; 5). However, the underlying mechanisms that 
allow the development and expansion of such disease-relevant CD8
+
 T cell populations 
remain obscure. In this study, we generated fixed TRAV8-1/TRAJ9 chain NOD mice 
(designated A22 for simplicity to reflect usage of mouse line 22) (29) with either normal PI1 
and PI2 levels (A22Cα
-/-
 mice), PI2 overexpression (A22Cα
-/-
PI2
tg 
mice), PI2 deficiency 
(A22Cα
-/-
PI2
-/-
 mice), PI1 deficiency (A22Cα
-/-
PI1
-/-
mice), or both PI1 and PI2 deficiency 
with a mutant transgene preventing recognition of the insulin B15-23 peptide (A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice) (Table 1). These unique models were then used to investigate the role of PI 
expression on the insulin B15-23-reactive CD8
+
 T cell repertoire.
	 6	
Research Design and Methods 
Mice 
Insulin B15-23-reactive TRAV8-1/TRAJ9 TCRα chain transgenic mice were generated as 
described previously (29). Line 22 was selected for further characterization, hence the 
designation A22. TCRα chain transgenic mice were crossed with NODCα
-/-
 mice to generate 
A22Cα
-/-
 mice exclusively expressing the TRAV8-1/TRAJ9 transgene. These A22Cα
-/-
 mice 
were then crossed with NOD mice overexpressing PI2 under the MHCII promoter 
(NODPI2
tg
) to generate A22Cα
-/-
PI2
tg
 mice. In addition, A22Cα
-/-
 mice were crossed with 
NOD mice lacking PI2, NOD mice lacking PI1, and NOD mice lacking PI1 and PI2 but 
reconstituted with a mutant transgene encoding a tyrosine-to-alanine mutation at position 16 
of the insulin B chain (9) to generate A22Cα
-/-
PI2
-/-
 mice, A22Cα
-/-
PI1
-/-
 mice, and A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice, respectively (Table 1). Mice were housed in microisolators or 
scantainers in the specific pathogen-free facility at Cardiff University. All procedures were 
performed in accordance with protocols approved by the UK Home Office. 
Flow cytometric analysis of TCRVβ expression 
Thymus, spleen, pancreatic lymph nodes (PLN), and mesenteric lymph nodes (MLN) were 
harvested from mice aged 4-7 weeks, 8-10 weeks, and 12-16 weeks. Single cell suspensions 
were generated and stained with mAbs specific for CD4, CD8α, CD19, and 14 distinct 
TCRVβ chains (2-14 and 17). Live single CD8
+
 T cells were then gated to visualize TCRVβ 
expression patterns. Data were analyzed with FlowJo software version 7.6.5 (Treestar Inc.).  
Tetramer analysis 
Thymus, spleen, PLN, and MLN were harvested from TCRα transgenic mice and polyclonal 
NOD mice at 4-8 weeks of age. Single cell suspensions were generated and stained serially 
with pre-titrated concentrations of the H-2K
d
-LYLVCGERG tetramer (National Institutes of 
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Health Tetramer Core Facility), a viability dye, and the following mAbs: αCD4-PECy7, 
αCD8α-FITC, αCD11b-APC, and αCD19-PerCPCy5.5. Data were analyzed with FlowJo 
software version 7.6.5 (Treestar Inc.). T cells from G9C8 transgenic mice (29) were used as a 
positive control. The minimal H-2K
d
-AYAAAAAAV tetramer was used to determine non-
specific background.  
TRBV19
+
CD8
+
 T cell isolation and expansion 
Single cell PLN suspensions from 6-week-old A22Cα
-/-
 mice, A22Cα
-/-
PI2
-/-
 mice, and 
A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice were sorted by flow cytometry for live CD4
-
CD8
+
CD11b
-
CD19
-
TCRVβ6
+
 events. Cells were initially cultured in bulk with the addition of IL-2 
(20U/ml), IL-7 (2ng/ml), and insulin B15-23 peptide (1µg/ml) in RPMI complete medium 
(2mM L-glutamine, 100U/ml penicillin, 0.1mg/ml streptomycin, 5% fetal bovine serum, and 
0.05mM 2-mercaptoethanol in RPMI 1640). Expanding cells were re-plated after limiting 
dilution and grown to sufficient numbers for functional analysis. 
Cytotoxicity assays 
Expanded TRBV19
+
CD8
+
 T cells were washed twice in RPMI complete medium to remove 
cytokines from the culture. P815 cells (targets) were labeled with PKH-26 (Sigma) and 
incubated with TRBV19
+
CD8
+
 T cells (effectors) in the presence of insulin B15-23 peptide at 
an effector-to-target (E:T) ratio of 10:1 for 16 hours at 37°C. TOPRO-3 iodide was added 
immediately prior to flow cytometric analysis. Single PKH-26
+
TOPRO-3
+
 P815 cells were 
gated, and cytotoxicity was expressed as the percentage of dead cells/total targets (30). 
Specific target cell killing was corrected for spontaneous background death by subtracting the 
percentage of dead cells in the control sample comprising targets with T cells in the absence 
of peptide.   
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Enzyme-linked immunosorbent assays 
TRBV19
+
CD8
+
 T cells were co-cultured with irradiated bone marrow-derived dendritic cells 
in the presence of insulin B15-23 peptide at an E:T ratio of 10:1 for 48 hours at 37°C. 
Supernatants were analyzed for MIP1β and IFNγ levels according to the manufacturer’s 
instructions (R&D Systems and eBioscience, respectively).  
TCR clonotyping 
Clonotypic analysis of H-2K
d
-LYLVCGERG tetramer
+
CD8
+
 T cells and oligoclonal lines 
was performed as described previously with minor modifications (31). Briefly, viable 
tetramer
+
CD8
+
 T cells (n=43-2,353) from individual mice or TRBV19
+
CD8
+
 T cells 
(n=5,000) from individual oligoclonal lines were sorted directly into 1.5ml microtubes 
(Sarstedt) containing 100µl RNAlater (Applied Biosystems) using a custom-modified FACS 
Aria II flow cytometer (BD Biosciences). Unbiased amplification of all expressed TRBV gene 
products was conducted using a template-switch anchored RT-PCR with a 3' constant region 
primer (5'-TGGCTCAAACAAGGAGACCT-3'). Amplicons were sub-cloned, sampled, 
sequenced, and analyzed as described previously (32). Concatenated data are shown for each 
genetic strain. The IMGT nomenclature is used in this report (33). 
Histology 
Immunohistochemistry was performed on fixed pancreata as described previously (29). 
Sections were scored for insulitis after staining with hematoxylin and eosin (Vector 
Laboratories). 
Statistics 
Statistical analyses were conducted using ANOVA tests or Student’s t-test with R software. 
Bonferroni correction was used for multiple comparisons such that p<0.05 is equivalent to 
p<0.0000022907 and p<0.01 is equivalent to p<0.0000004581.  
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Results 
CD4
+
 and CD8
+
 T cell numbers are not affected by PI expression 
In preliminary experiments, we used flow cytometry to assess the impact of PI expression on 
T cell lineage development in our mouse models (A22Cα
-/-
, A22Cα
-/-
PI2
tg
, A22Cα
-/-
PI2
-/-
, 
A22Cα
-/-
PI1
-/-
, and A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
). Groups of mice were screened at 4-7 weeks 
and 12-16 weeks. No significant differences in CD4
+
 or CD8
+
 T cell numbers were apparent 
between strains regardless of age, either in the thymus (Figure 1) or in the periphery 
(Supplemental Figure 1). However, a substantial reduction in the total number of CD4
+
 T 
cells was observed for all TCRα chain transgenic strains relative to polyclonal NOD mice 
(Figure 1 and Supplemental Figure 1). 
PI expression alters the proportion of TRBV19
+
CD8
+
 T cells 
To evaluate the global influence of PI expression on the CD8
+
 T cell repertoire, 14 TCRVβ-
specific mAbs were used to assess TRBV usage by CD8
+
 T cells isolated from the thymus, 
spleen, and lymph nodes of the different A22Cα
-/-
 mice aged either 4-7 weeks or 12-16 
weeks. A strong PI-mediated effect was observed on the expression of TRBV19 (Vβ6), 
which encodes the TCRVβ chain used by the G9C8 clone (Figure 2 and Supplemental Figure 
2). Specifically, the proportion of TRBV19
+
CD8
+
 T cells, both in the thymus and the 
periphery, decreased with age in A22Cα
-/-
 mice (Figure 2). This effect was more pronounced 
in mice with PI2 overexpression (A22Cα
-/-
PI2
tg
), which also displayed lower proportions of 
TRBV19
+
CD8
+
 T cells compared to A22Cα
-/- 
mice, notably approximating those observed in 
polyclonal NOD mice. However, mice lacking PI1 (A22Cα
-/-
PI1
-/-
), PI2 (A22Cα
-/-
PI2
-/-
), or 
both PI genes (A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
) showed no significant changes in the proportion of 
TRBV19
+
CD8
+
 T cells with age. Similar trends were observed with respect to the absolute 
number of TRBV19
+
CD8
+
 T cells, which declined with age but differed between strains only 
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in PLN at 12-16 weeks, where a substantial reduction was observed in A22Cα
-/-
PI2
tg
 mice 
(Supplemental Figure 2). Less marked effects were noted with other TRBV segments. In 
particular, the proportion of CD8
+
 T cells expressing TRBV13 (Vβ8), the most commonly 
employed gene segment in NOD mice, was unaffected by proinsulin expression (data not 
shown).  
Insulin B15-23-reactive CD8
+
 T cells are increased in mice lacking PI1 or PI2 
As the TRAV8-1/TRAJ9 chain used by these mice specifically recognizes the insulin B15-23 
epitope, we used H-2K
d
-LYLVCGERG tetramers to quantify the effect of PI expression on 
the development of insulin B15-23-reactive CD8
+
 T cells (Supplemental Figure 3A). 
Increased numbers and percentages of tetramer
+
CD8
+
 T cells were detected in the thymus, 
spleen, and PLN of PI2 deficient (A22Cα
-/-
PI2
-/-
) mice compared to wildtype A22Cα
-/-
 mice 
(Figure 3 and Supplemental Figure 3). Interestingly, A22Cα
-/-
PI1
-/-
 mice also showed an 
increased proportion of insulin B15-23-reactive CD8
+
 T cells in PLN compared to A22Cα
-/-
 
mice, whereas a smaller increase was observed in PLN from A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice 
despite greater enhancements in the thymus and spleen. However, only the A22Cα
-/-
PI2
-/-
 and 
A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 strains exhibited an increase in the number of insulin B15-23-
reactive CD8
+
 T cells in both the thymus and the periphery (Supplemental Figure 3B). It is 
also notable that no differences in tetramer staining intensity were detected between strains, 
indicating equivalent levels of cognate TCR expression (Supplemental Figure 3C). 
Insulin B15-23-reactive CD8
+
 T cells cause spontaneous diabetes in PI2 deficient mice  
To assess the biological relevance of these proportional and numerical differences in insulin 
B15-23-reactive CD8
+
 T cells, we examined the incidence of spontaneous diabetes across 
strains. Strikingly, diabetes occurred spontaneously only in male PI2 deficient (A22Cα
-/-
PI2
-/-
) mice (Figure 4). Moreover, disease onset was considerably accelerated in this group 
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compared to male wildtype NOD mice, which develop diabetes after 20 weeks of age in our 
colony with a final incidence of 20% by 35 weeks (data not shown). Mild insulitis was 
detected in male A22Cα
-/- 
and non-diabetic A22Cα
-/-
PI2
-/- 
mice, while normal pancreatic 
histology was observed in male A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice (Supplemental Table 1). 
These findings suggest that PI2 deficiency permits the development of diabetogenic insulin 
B15-23-reactive CD8
+
 T cells. 
Insulin B15-23-reactive CD8
+
 T cells express multiple TRBV chains and exhibit PI-
specific changes in TRBV19 usage  
To further our understanding of the diabetogenic process, we evaluated the TCR repertoire 
specifically within the insulin B15-23-reactive CD8
+
 T cell population. Data are shown for 
wildtype mice (A22Cα
-/-
), PI2 overexpressing mice (A22Cα
-/-
PI2
tg
), PI2 deficient mice 
(A22Cα
-/-
PI2
-/-
), and mice lacking both PI1 and PI2 (A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
). By 
sequencing expressed TRB transcripts in H-2K
d
-LYLVCGERG tetramer
+
CD8
+
 T cells from 
PLN, we identified a restricted TCR repertoire in all four groups of mice (Figure 5). 
Alterations in PI expression clearly influenced TRBV gene selection in insulin B15-23-
reactive CD8
+
 T cells. Most notably, the proportion of TRBV19
+
CD8
+
 T cells increased 
when PI2 or both PI1 and PI2 were absent. Moreover, no TRBV19 sequences were detected 
when PI2 was overexpressed. These observations suggest that PI expression critically affects 
the selection of insulin B15-23-reactive TCRs, even in the context of a highly restricted 
clonotypic repertoire. 
Insulin B15-23-reactive TRBV19
+
CD8
+
 T cells exhibit low functional sensitivity 
irrespective of PI expression during development 
As the selection of insulin B15-23-reactive TRBV19
+
CD8
+
 T cells was influenced by PI 
expression, we next investigated the role of antigen exposure as a determinant of cellular 
function. TRBV19
+
CD8
+
 T cells from wildtype (A22Cα
-/-
), PI2 deficient (A22Cα
-/-
PI2
-/-
), or 
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PI1 and PI2 deficient (A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
) mice were isolated and cultured briefly with 
the cognate peptide in the presence of IL-2 and IL-7 to generate a panel of insulin B15-23-
reactive oligoclonal T cell lines. The functional profile of these lines was assayed by 
measuring cytotoxicity and proinflammatory cytokine (MIP1β and IFNγ) production in 
response to the insulin B15-23 peptide. Similar cytotoxic responses were observed for all 
strains regardless of PI expression, and target cell lysis required high doses of exogenous 
peptide (Figure 6A). Lines generated from A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice displayed 
enhanced MIP1β responses (Figure 6B) but produced less IFNγ compared to wildtype 
(Figure 6C). Overall, these results suggest that insulin B15-23-reactive TRBV19
+
CD8
+
 T 
cells exhibit intrinsically low levels of functional sensitivity and that altered reactivity to 
cognate antigen does not underlie the development of spontaneous diabetes in PI2 deficient 
(A22Cα
-/-
PI2
-/-
) mice. 
Insulin B15-23-reactive TRBV19
+
CD8
+
 T cells use TRBJ2-3 and exhibit a common TCR 
CDR3β  motif  
The highly diabetogenic G9C8 clone expresses a TRBV19/TRBJ2-3 gene-encoded TCRβ 
chain (22). Although no obvious differences in functional sensitivity were observed between 
insulin B15-23-reactive CD8
+
 T cell clonotypes selected in mice with differing levels of PI 
expression, we nonetheless conducted a molecular analysis of TRB gene rearrangements in 
our oligoclonal antigen-specific lines to see if PI expression impinges on TCR selection. All 
lines were dominated by TRBV19
+
 TCRs, and 9 of the 20 were monoclonal. We obtained 11 
unique TRBV19-associated CDR3β sequences, 5 of which were private and 6 of which were 
shared (Table 2). Ten of these distinct CDR3β sequences incorporated TRBJ2-3 with a fixed 
loop length of 13 amino acids generating a motif (CASS-XXXX-GAETLY) in common with 
the original G9C8 clone (CASS-IRDR-GAETLY). Moreover, arginine was universally 
conserved at position 6 in these CDR3β sequences, likely providing an important contact 
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residue for recognition of the insulin B15-23 peptide. Non-polar side chain amino acids were 
preferred at position 5 (with the exception of arginine), whereas amino acids with acidic side 
chains (aspartic acid or glutamic acid) or uncharged polar side chains (glutamine or 
threonine) were preferred at position 7. Little preference was observed for any particular 
residue at position 8. In contrast, we found very limited sequence similarity across the 
CDR3β loop within the tetramer
+
CD8
+
 T cell population as a whole (Figure 3). One common 
CDR3β sequence (CASSLGGYEQY) was found in A22Cα
-/-
 and A22Cα
-/-
PI2
-/-
 mice, and 
another (CASSRVPGEQY) was found in more than one A22Cα
-/-
 mouse (Supplemental 
Table 2). We also examined sequences of TRBV19+ non-insulin B15-23 reactive T cells in 
each of the 4 strains of transgenic mice.  We noted that the TRBJ2-3 incorporated motif 
(CASS-XXXX-GAETLY) was not found in these T cells (data not shown).  Collectively, 
these data demonstrate that insulin B15-23 elicits a highly biased TRBV19
+
 repertoire 
consistent with a strict docking mode for TCR recognition dictated by structural constraints.   
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Discussion 
In this paper, we report five principal findings based on an in-depth analysis of fixed 
TCRα chain NOD mice. First, PI1 or PI2 deficiency is associated with peripheral expansion 
and significant increases in insulin B15-23-reactive CD8
+
 T cells in the draining lymph node 
for the pancreas, the target organ in type 1 diabetes. Second, the proportion of insulin B15-
23-reactive CD8
+
 T cells expressing TRBV19 increases in the absence of PI. This repertoire 
shift potentially contributes to the development of autoimmune diabetes. Third, variations in 
PI expression alter global TRBV gene usage in the CD8
+
 T cell compartment. In particular, 
TRBV19
+
CD8
+
 T cell numbers were reduced significantly upon increased exposure to PI2 
through transgenic overexpression, although deletion of either the PI1 or PI2 genes alone did 
not change the frequency of this population. Fourth, insulin B15-23-reactive TRBV19
+
CD8
+
 
T cells display low levels of functional sensitivity for the cognate peptide irrespective of PI 
expression, consistent with a lack of epitope-regulated negative selection in the thymus. Fifth, 
antigen recognition by insulin B15-23-reactive TRBV19
+
CD8
+
 T cells is driven by a highly 
biased set of TCRs characterized by TRBJ2-3 gene usage and the presence of a conserved 
non-germline-encoded arginine residue at position 6 in the CDR3β loop. To our knowledge, 
this is the first demonstration that proinsulin expression can directly affect the development 
of autoreactive TCRs. 
PI2 is expressed in the thymus and has been shown to promote tolerance (17; 20; 21; 
34). As a consequence, NOD mice with PI2 deficiency develop accelerated diabetes (19). 
However, NOD mice lacking PI1 do not develop autoimmune diabetes, presumably because 
PI2 tolerizes potentially autoreactive T cells (18). Although both PI1 and PI2 are expressed in 
the thymus, PI2 is the predominant isoform; equivalent levels of PI1 and PI2 are found in the 
periphery (17; 35; 36). It is notable in this regard that PI deficiency enhanced the 
development of TRBV19
+
CD8
+
 T cells in the thymus and minimized corresponding age-
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related declines in the periphery. These data suggest that both PI1 and PI2 have tolerogenic 
properties, with the weak effects on disease likely related to the low frequency of insulin 
B15-23-reactive cells in the overall TRBV19
+
CD8
+
 T cell population. 
Antigen encounter in the thymus preferentially deletes high avidity T cells (37; 38). 
Consistent with this process, our data show that increased numbers of insulin B15-23-reactive 
CD8
+
 T cells are present in mice lacking either PI2 alone or both PI1 and PI2, probably due 
to a lack of negative selection. Moreover, only PI2 deficient mice developed diabetes in our 
study. It is remarkable that male mice were exclusively affected in this regard, despite 
equivalent increases in insulin-reactive CD8
+
 T cells in female mice lacking PI2. Recent data 
suggest that non-immune factors, including interactions between gut microbiota and 
androgens (39; 40), may contribute to such sexual dimorphism in the development of 
diabetes. Irrespective of the underlying mechanism, however, these findings suggest that 
insulin B15-23-reactive CD8
+
 T cells are important determinants of disease because A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
 mice express a mutant transgene that prevents recognition of the cognate 
peptide.   
It is notable that we did not detect any significant functional differences in insulin 
B15-23-reactive TRBV19
+
CD8
+
 T cells across strains of mice with altered levels of PI 
expression. This counterintuitive finding may reflect in vitro activation and expansion prior 
to assay, which could mask intrinsic differences in the ex vivo setting, or a convergence of 
functional properties due to the expression of PI in peripheral lymphoid tissue (13; 41). 
Regardless of origin, these autoreactive cells expressed very similar TRBV19/TRBJ2-3 
transcripts incorporating a CDR3β motif based around a central arginine residue. Arginine is 
degenerately encoded at the nucleotide level and readily incorporated on a probabilistic basis 
during the somatic recombination process (42). It can also play a key role in TCR recognition 
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(43). Our data therefore suggest a highly conserved mode of antigen engagement focused on 
the G9C8 ‘blueprint’. 
Several studies have previously identified a tolerogenic role for PI2 (17; 19; 20; 21). 
In contrast, the role of PI1 has not been fully established. The only reported investigation in 
NOD mice found that PI1 deficiency protected against the development of diabetes (18). 
Interestingly, on a non-autoimmune background (129/SV), mice lacking PI2 showed 
increased PI1 gene transcripts as well as enhanced β cell mass to compensate for lower 
insulin production, indicating the importance of PI1 in metabolism (44). Moreover, the PI2 
B9-23 peptide can induce proliferation of PI1-reactive NOD T cells, and both the PI1 B9-23 
and C49-66 peptides can induce proliferation of PI2-reactive NOD T cells (21). Such cross-
reactivity suggests that both isoforms can facilitate the expansion of PI-specific populations 
in the periphery. Further studies are therefore required to assess the relative contributions of 
PI1 and PI2 as determinants of tolerance and diabetogenicity. 
Although our model system addresses a single specificity, the epitope nonetheless 
derives from insulin, which is known to be an important early antigenic target in type 1 
diabetes. Previous work by other investigators has focused on IGRP-specific NY8.3 CD8
+
 T 
cells (45-47). However, there are fundamental differences between these two diabetogenic 
epitopes. Most notably, IGRP is not expressed in the thymus (1). In contrast, studies of 
proinsulin facilitate an understanding of repertoire development in the presence of an 
autoantigen that is naturally expressed in the thymus and the periphery. Moreover, IGRP 
reactivity is dependent on an autoimmune response to insulin (24; 25). In humans, the key 
genetic susceptibility region IDDM2 relates to the level of proinsulin expression. Our study is 
therefore informative because it describes the impact of variable proinsulin expression on 
clonotype selection in response to a defined and biologically relevant autoimmune epitope in 
type 1 diabetes. 
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Two important conclusions emerge from the present data. First, proinsulin expression 
shapes the insulin-reactive CD8
+
 T cell repertoire in a mouse model of type 1 diabetes. 
Second, an avidity threshold exists below which insulin-reactive CD8
+
 T cells are less 
affected by antigen exposure in the thymus compared to the periphery. These findings have 
potential implications for the induction of antigen-specific tolerance as a therapeutic strategy 
against autoimmune diabetes.  
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Genotype TCRα	chain TCRβ	chain Proinsulin	1	
expression 
Proinsulin	2	
expression 
Diabetes 
A22Cα
-/- 
G9	TCRα	
transgene	
(insulin	B15-
23-specific) 
Endogenous	
TCRβ	chains	 
Normal Normal No	diabetes 
A22Cα
-/-
PI2
tg 
G9	TCRα	
transgene	
(insulin	B15-
23-specific) 
Endogenous	
TCRβ	chains	 
Normal 
Overexpression	
(under	MHCII	
promoter) 
No	diabetes 
A22Cα
-/-
PI1
-/- 
G9	TCRα	
transgene	
(insulin	B15-
23-specific) 
Endogenous	
TCRβ	chains	 
Deficient Normal No	diabetes 
A22Cα
-/-
PI2
-/- 
G9	TCRα	
transgene	
(insulin	B15-
23-specific) 
Endogenous	
TCRβ	chains	 
Normal Deficient 
Accelerated	
diabetes	in	
males 
A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg 
G9	TCRα	
transgene	
(insulin	B15-
23-specific) 
Endogenous	
TCRβ	chains	 
Lack	both	native	proinsulin	
genes	but	express	a	mutated	
insulin	transgene 
No	diabetes 
Table 1: Transgenic and knockout mice used in this study. 
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DONOR	STRAIN	 ID	 TRBV	 CDR3β 	SEQUENCE	 TRBJ	 FREQUENCY	(%)	
A22Cα-/-	
10F11	 19	 CASSIRTGGAETLY 2-3	 100	
10F12	 19	 CASSMRQGGAETLY 2-3	 100	
30B6	
19	 CASSIRQGGAETLY 2-3	 94.74	
19	 CASSIRQGDAETLY 2-3	 5.26	
30C4	
19	 CASSMRQGGAETLY 2-3	 88.89	
19	 CASSRRDRGAETLY 2-3	 11.11	
30D7	
19	 CASSSGLEQY 2-7	 93.75	
19	 CASSFREEGAETLY 2-3	 6.25	
30F7	
19	 CASSIRTGGAETLY 2-3	 94.12	
24	 CASSRDSDTEVF 1-1	 5.88	
A22Cα-/-PI2-/-	
1F9	
19	 CASSIRQGGAETLY 2-3	 96	
19	 CASSFREEGAETLY 2-3	 4	
30A6	 19	 CASSFREEGAETLY 2-3	 100	
30B9	
19	 CASSMRQGGAETLY 2-3	 69.23	
19	 CASSFREEGAETLY 2-3	 23.08	
19	 CASSIREGGAETLY 2-3	 7.69	
30D4	
19	 CASSIRQGGAETLY 2-3	 94.12	
19	 CASSVRQGGAETLY 2-3	 5.88	
30D8	
19	 CASSFREEGAETLY 2-3	 50	
19	 CASSIRQGGAETLY 2-3	 25	
19	 CASSFRQEGAETLY 2-3	 16.67	
19	 CASSMRQRGAETLY 2-3	 8.33	
30H3	 19	 CASSIRQGGAETLY 2-3	 100	
A22Cα-/-PI1-/-
PI2-/-Y16Atg	
1G3	 19	 CASSMRQGGAETLY 2-3	 100	
3F11	
19	 CASSMRQGGAETLY 2-3	 63.64	
19	 CASSRRDRGAETLY 2-3	 31.82	
4	 CASSQDGQDTQY 2-5	 4.55	
3G5	 19	 CASSIRQGGAETLY 2-3	 100	
10G2	
19	 CASSMRQGGAETLY 2-3	 58.33	
19	 CASSFREEGAETLY 2-3	 33.33	
19	 CASSFRQEGAETLY 2-3	 8.33	
30A8	 19	 CASSMRQGGAETLY 2-3	 100	
30B8	 19	 CASSMRQGGAETLY 2-3	 100	
30E2	
19	 CASSIRTGGAETLY 2-3	 61.9	
19	 CASSMRQGGAETLY 2-3	 33.33	
19	 CASSFREEGAETLY 2-3	 4.76	
30H1	 19	 CASSIRQGGAETLY 2-3	 100	
Table 2: CDR3β sequences of insulin B15-23-reactive oligoclonal lines. Colored sequences 
represent those found in more than one mouse. Non-germline-encoded motifs are underlined in bold. 
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Figure Legends 
Figure 1. CD4
+
 and CD8
+
 T cell numbers in the thymus are unaffected by proinsulin 
expression 
Live single-positive CD4
+
 and CD8
+
 T cells were quantified in single cell suspensions of 
thymus from mice aged 4-7 or 12-16 weeks. Representative flow cytometry plots (A), total 
CD4
+
 T cell numbers (B), and total CD8
+
 T cell numbers (C) are displayed for all strains. 
Data are shown for 9-12 mice per group (encompassing 3-4 experiments). Males and females 
were included as no differences were detected when analyzed separately. Significance was 
assigned at p<0.01 (**). 
Figure 2. Proinsulin-specific and age-related effects on TRBV19 expression 
CD8
+
 T cells expressing TCRVβ6 (TRBV19) were quantified in single cell suspensions of 
thymus (A, B) and pancreatic lymph nodes (PLN) (C, D) from mice aged 4-7 (A, C) or 12-16 
(B, D) weeks. Data are shown for 9-12 mice per group (encompassing 3-4 experiments). 
Males and females were included as no differences were detected when analyzed separately. 
Significance was assigned at p<0.05 (*) and p<0.01 (**). 
Figure 3. PI2 deficiency increases the proportion of insulin B15-23-reactive CD8
+
 T cells  
H-2K
d
-LYLVCGERG tetramer
+
CD8
+
 T cells were quantified in single cell suspensions of 
thymus, spleen, pancreatic lymph nodes (PLN), and mesenteric lymph nodes (MLN) from 
mice aged 4-8 weeks. Non-specific staining was quantified using the minimal H-2K
d
-
AYAAAAAAV tetramer. Data are shown after background subtraction for 5-10 mice per 
group. Males and females were included as no differences were detected when analyzed 
separately. Significance was assigned at p<0.05 (*) and p<0.01 (**). 
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Figure 4. Mice deficient in PI2 develop spontaneous diabetes  
Mice were housed together from weaning and tested weekly for glycosuria using Diastix. 
Positive results were validated 24 hours later, and diabetes was confirmed by a blood glucose 
level >13.9mmol/l. Only males were included as no females developed diabetes. Significance 
was assigned at p<0.05 (*). 
Figure 5. The TCRVβ repertoire of insulin B15-23-reactive CD8
+
 T cells  
H-2K
d
-LYLVCGERG tetramer
+
CD8
+
 T cells were sorted by flow cytometry from single cell 
suspensions of pancreatic lymph nodes (PLN) from mice aged 4-8 weeks and analyzed for 
TRB gene expression using an unbiased molecular approach. Data are shown for 5-7 mice per 
group, comprising a total of 6-20 distinct clonotypes. 
Figure 6. TRBV19
+
CD8
+
 T cells exhibit low levels of functional sensitivity to insulin 
B15-23  
Oligoclonal TRBV19
+
CD8
+
 T cell lines expanded in the presence of insulin B15-23 were 
analyzed for cytotoxic activity (A), MIP1β (B), and IFNγ (C) production. Data are shown for 
representative clones (A22Cα
-/-
: 10F12; A22Cα
-/-
PI2
-/-
: 30A6; A22Cα
-/-
PI1
-/-
PI2
-/-
Y16A
tg
: 
1G3). 
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SUPPLEMENTAL TABLE 1: Insulitis scores in non-diabetic mice at 20 
weeks of age. 
Strain Insulitis score 
 0 1 2 3 
A22Cα-/-  75.3% 12.7% 12% 0 
A22Cα-/-PI2-/-  76.7% 11.9% 11.9% 2.0% 
A22Cα-/-PI1-/-PI2-/-
Y16Atg  
100% 0 0 0 
 
Insulitis scores are shown for 96-144 islets from 3-7 mice per group.  The 
following criteria were used: 0, no insulitis, 1, peri-insulitis, 2, <50% of islet 
infiltrated 3, >50% of islet infiltrated.  
 
SUPPLEMENTAL TABLE 2: CDR3β sequences of insulin B15-23-reactive 
CD8+ T cells 
Colored sequences represent those found in more than one mouse. 
Strain CDR3β sequence Freq. (%) 
A22Cα-/- 
CASSLGGYEQY 35.16 
CASGDWGGYQDTQY 1.15 
CASSFILGGYAEQF 12.68 
CASSDYGDANTEVF 5.48 
CASTRHHTEVF 4.61 
CASTGNTGQLY 0.58 
CASSQDRSNTEVF 7.20 
CASSRVPGEQY 14.12 
CASSRAPGEQY 0.29 
CAGSRVPGEQY 0.29 
CASLVETLY 12.68 
CASSDAWAGGQDTQY 5.48 
CASLAETLY 0.29 
A22Cα-/-PI2tg 
CASRRDIYNSPLY 91.71 
CASGPGTGGFTEVF 6.08 
CASSRDIYNSPLY 2.21 
A22Cα-/-PI2-/- 
CASSIRESGAETLY 12.94 
CASSRDNTEVF 2.41 
CASSLVSQDTQY 2.19 
CASGDAVEQY 2.19 
CASSHRGNTEVF 15.57 
CVSSHRGNTEVF 0.88 
CASSHRGNTEAF 0.22 
CASSEGQGGDTQY 17.54 
CAGSEGQGGDTQY 0.22 
CASSLGGYEQY 13.60 
CASSLGGYGQY 4.61 
CASRSGGTGNTLY 2.19 
CASRSGGPGNTLY 0.22 
CASSLDRNQNTLY 20.61 
CASSYRGPNQDTQY 4.61 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
CASSPAGSTLY 28.46 
CASSLTGNTGQLY 2.44 
CASSGDYAEQF 32.93 
CAWSLAGGGQY 0.81 
CASSPDNYEQY 29.67 
CTCSADYAEQF 5.69 
